CNS Pharmaceuticals (CNSP) Other Non-Current Assets (2018 - 2025)
CNS Pharmaceuticals' (CNSP) quarterly Other Non-Current Assets came in at $502962.0 in Q4 2025, up 1280.63% YoY from $36430.0 in Q4 2024, and up 6.02% on a QoQ basis from $474416.0 in Q3 2025.
CNS Pharmaceuticals (CNSP) Other Non-Current Assets (2018 - 2025) Analysis & Trends
CNS Pharmaceuticals (CNSP) has 6 years of Other Non-Current Assets data on file, last reported at $502962.0 in Q4 2025.
- Quarterly Other Non-Current Assets rose 1280.63% year-over-year to $502962.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $502962.0 (up 1280.63% YoY) and the FY2025 annual result came in at $502962.0, up 1280.63% from the prior year.
- Other Non-Current Assets rose to $502962.0 in Q4 2025, from $474416.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $929688.0 in Q4 2021 to a low of $18373.0 in Q3 2024.
- A 5-year average of $381367.7 and a median of $377196.0 in 2023 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2024 — Other Non-Current Assets tumbled 93.01% — and 2025, when it soared 2482.14%.
- Tracing CNSP's Other Non-Current Assets over 5 years: stood at $929688.0 in 2021, then slumped by 48.07% to $482806.0 in 2022, then plunged by 78.3% to $104750.0 in 2023, then slumped by 65.22% to $36430.0 in 2024, then surged by 1280.63% to $502962.0 in 2025.
- The last three Other Non-Current Assets figures came in at $502962.0 (Q4 2025), $474416.0 (Q3 2025), and $366251.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | CNS Pharmaceuticals | 2.65 Mn | -4.55 Mn | - | 502,962.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 502,962.00 |
| Sep 30, 2025 | 474,416.00 |
| Jun 30, 2025 | 366,251.00 |
| Mar 31, 2025 | 22,384.00 |
| Dec 31, 2024 | 36,430.00 |
| Sep 30, 2024 | 18,373.00 |
| Jun 30, 2024 | 320,320.00 |
| Mar 31, 2024 | 55,296.00 |
| Dec 31, 2023 | 104,750.00 |
| Sep 30, 2023 | 262,731.00 |
| Jun 30, 2023 | 377,196.00 |
| Mar 31, 2023 | 438,131.00 |
| Dec 31, 2022 | 482,806.00 |
| Sep 30, 2022 | 594,898.00 |
| Jun 30, 2022 | 704,794.00 |
| Mar 31, 2022 | 791,825.00 |
| Dec 31, 2021 | 929,688.00 |
| Dec 31, 2018 | 95,200.00 |